Voluntary nationwide recall: Duloxetine (Towa – October)

Dec. 2024Pharmacy Updates

Towa Pharmaceutical is recalling one lot, lot 220128, of Duloxetine Delayed-Release Capsules, USP, 20 mg. Duloxetine is used to treat anxiety, depression, and certain types of nerve pain.

This drug is being recalled because it contained an impurity called N-nitroso-duloxetine. According to the FDA, nitrosamine impurities may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time. Additionally, the FDA added that someone who is taking a drug that contains nitrosamines at or below the acceptable daily intake limits every day for several years is not expected to have an increased risk of cancer.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA report and website below. If you have an affected lot of Duloxetine, The FDA advises that you should stop using the product and return it to the place of purchase or throw it away.

As of Oct. 23, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.


Recent Announcements

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Oct. 2026Education/Webinars

CME Webinar: Navigating Grief Conversations

Please join us for a live, CME-accredited webinar on Thursday, Nov. 12, 2026, that will enhance your confidence and effectiveness in supporting patients dealing with loss & grief.
Oct. 2026Education/Webinars

Provider OnLine Login Changes for UPMC Employees and UPMC Children’s Hospital of Pittsburgh Employees

UPMC employees and UPMC Children’s Hospital of Pittsburgh employees will now use their email address to access Provider OnLine.
Oct. 2026Important Notices